Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Links shared publicly online about this topic.

809
total visits

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

View full resource at news-medical.net

Tags: Genetic, Cancer, Non-Small Cell Lung Cancer Medication, Skin Cancer, Squamous Cell Carcinoma, Alimta, Eli Lilly and Company, News